Accelerating Genomics and Precision Medicine through Innovation in APAC

Abstract:

Genomic data is transforming drug discovery, but processing these massive datasets demands high-performance, scalable, and cost-efficient computing. Modern genomics platforms now enable researchers to accelerate analysis, optimise sequential workflows, and reduce cost-per-genome without relying on specialty hardware. By supporting predictive, diagnostic, and pharmacogenomic testing at speed and scale, these tools help clinical teams pinpoint causal mutations, validate disorders, and understand drug response mechanisms, shortening time to insight and strengthening competitiveness in a rapidly evolving life sciences landscape.

1. How is the rapid expansion of genomic datasets in APAC reshaping the region’s approach to precision medicine, and what innovations are most critical to sustaining this momentum?

APAC’s genomic expansion now enables population-scale discovery and near-real-time clinical genomics. Leading institutions such as the University of Delhi, one of India’s top research universities, are now processing a 30× human genome in just 1.3 hours, achieving a 36× speed-up that allows both plant omics and human disease programs to scale dramatically. Platforms that can process large cohorts quickly, operate within sovereignty constraints, and support multi-omics workflows are necessary. Innovations such as CPU-tuned secondary analysis pipelines, standardised variant-calling workflows, and secure hybrid environments are essential to sustain progress.

2. What are the biggest computational bottlenecks in large-scale genomic analysis today, and how are modern platforms addressing challenges around speed, scalability, and cost-per-genome?

Fragmented, inconsistent, and hard-to-govern data continues to be one of the biggest computational bottlenecks in large-scale genomic analysis. Skills gaps in areas like data security, compliance, lifecycle management, and workload optimisation further slow progress. Many healthcare IT environments were not built for high-volume genomic workloads, creating bottlenecks across compute, storage, and system integration. Next-generation HPC platforms delivering GPU-level performance on optimised CPUs at lower costs are helping boost capacity, reduce processing time, and accelerate research. 

3. APAC’s healthcare systems vary widely in maturity. How do these differences influence the adoption of high-performance genomics infrastructure across the region? 
 
Variation in readiness means APAC nations approach genomics at different scales. Advanced ecosystems move directly into population genomics, newborn whole-genome sequencing (WGS), and AI-augmented diagnostics. Emerging systems often start with smaller, genomics-tuned appliances or pilot networks, then expand as funding and workforce capacity grow. 

The regions benefit most from flexible, modular infrastructure that lets providers start small, expand steadily, and build toward national precision-health initiatives without overstretching resources.

4. To what extent is the shift from specialty hardware to software-driven, cloud-optimized genomic analysis redefining cost models for clinical and research institutions?

Software-driven and cloud-optimized genomics allows institutions to run validated workflows consistently across on-prem and hybrid environments, reducing reliance on costly specialty hardware. This aligns spending with sequencing throughput instead of capital-heavy systems. From our perspective, flexible hybrid models help keep sensitive datasets on trusted infrastructure while still benefiting from automated orchestration and pay-as-you-go access to high-performance resources. The result is better cost predictability, smoother scaling, and more efficient use of compute.

5. How can APAC healthcare ecosystems ensure equitable access to precision medicine, given disparities in digital infrastructure, genomic literacy, and research funding?

Equitable access depends on shared HPC resources, regionally adapted pipelines, and upskilling clinicians and bioinformaticians. Advanced hubs can support emerging markets by sharing reference datasets, training programs, and secure access to genomics infrastructure through managed networks. From our experience, public education and transparent governance of genomic data are equally important. Regional collaborations help countries with limited funding or digital maturity participate in larger precision-health initiatives and access high-quality molecular insights. 

6. What are the key considerations for integrating predictive, diagnostic, and pharmacogenomic testing into routine clinical workflows at population scale?

Successful integration requires reliable pipelines, unified data standards, and infrastructure that supports high-throughput analysis without disrupting clinical workflows. Institutions need platforms that deliver consistent performance, predictable turnaround times, and strong data governance. From our perspective, the priority is ensuring interoperability across labs, EHR systems, and national registries so clinicians can trust the outputs and act quickly. Workforce enablement and automated interpretation tools further help scale these services safely and efficiently.

7. How is the APAC regulatory environment evolving to support genomic innovation, and where do gaps still exist in terms of data governance and ethical oversight?

APAC regulators are strengthening rules around privacy, consent, and responsible data use as genomic datasets grow. Several markets are pairing fast-track pathways and strategic funds with clearer IP frameworks to support biotech and MedTech innovation. This creates more predictable routes from discovery to clinical readiness. Remaining gaps include harmonised data governance, cross-border trial alignment, and explicit guidance for algorithm-derived insights. Consistent regional standards will be essential for scaling genomics responsibly.

8. With increasing emphasis on early detection and personalised therapies, how is genomic data helping clinicians validate disorders and pinpoint causal mutations faster than before?

Genomic data accelerates diagnosis when combined with platforms engineered for bioinformatics. GOAST is a multi-purpose system designed specifically for genomics and multi-omics workloads. It uses carefully selected, high-core CPUs, fast I/O and large memory to run massively parallel workflows efficiently, cutting whole-genome mapping and variant calling from roughly 40 hours in typical data centers to about 23.5 minutes. In practice, this speeds iteration, narrows down causal mutations, and reduces diagnostic uncertainty, giving care teams the ability to intervene earlier with greater confidence. 

9. What strategies should healthcare and research organisations adopt to ensure security, privacy, and cross-border compliance when handling massive volumes of genomic data?

Organisations need multilayered protections that safeguard data wherever it resides, edge, core, or cloud. This includes secure boot, encrypted storage, tamper-proof snapshots, autonomous ransomware detection powered by machine learning, and continuous monitoring to identify anomalies early. Because genomic workloads demand high-performance infrastructure, energy-efficient, high-density systems with built-in resiliency features help minimise operational risk while supporting large-scale analysis. 

Unified platforms that enforce consistent policies, auditability, and access controls across distributed environments help maintain compliance and ensure trusted data sharing across borders while preserving patient privacy. 

10. How are AI and machine learning shaping next-generation genomic analytics, and what safeguards are necessary to ensure reproducibility, accuracy, and clinical trust?

AI and ML now enhance variant calling, annotation, and multi-omics integration, and are increasingly embedded into genomics pipelines. To maintain trust, models must be trained on diverse regional cohorts, independently validated, and monitored for drift. Hybrid approaches allow sensitive data to remain on trusted infrastructure while models execute securely. Transparent audit trails, explainability, and alignment with clinical guidelines ensure reproducibility and give clinicians confidence in when and how to rely on AI outputs. 

11. What opportunities exist for APAC countries to build regional genomic collaboratives, shared databases, or federated learning models to advance precision medicine?

APAC can advance precision medicine by building shared databases, federated learning networks, and cross-border research initiatives. Korea’s US$23bn strategic advanced industry fund and Australia’s growing clinical-trial ecosystem offer complementary strengths that could be connected to expand access to high-quality data. Shared efforts to improve genomic databases, strengthen data-sharing mechanisms, and expand access to molecular testing would help reduce misdiagnosis, support earlier and precise treatment selection, and accelerate R&D efforts. Markets with strong research ecosystems can support others through shared compute, training, and curated reference panels. 

12. How can life sciences organisations optimise end-to-end genomic workflows - from sample prep to interpretation - to reduce total turnaround times and improve competitiveness?

They can align workflow design with the realities of modern sequencing, where long-read datasets and expanding cohort sizes strain traditional compute. CPU-optimized algorithms, such as vectorized implementations of long-read mappers, now deliver significant speed-ups without relying on scarce GPUs, helping labs process urgent workloads immediately. When combined with hybrid AI, efficient data movement from edge instruments to high-performance compute, and automated interpretation pipelines, these optimizations reduce bottlenecks across mapping, variant calling, and annotation. The result is faster, more sustainable turnaround that keeps pace with advanced sequencing technologies and rising clinical expectations.

13. What role do public-private partnerships play in accelerating genomics innovation in APAC, particularly in areas like workforce development, national genome programs, and translational research?

Public-private partnerships help bridge the gap between discovery and real-world clinical adoption. Governments invest in translational funds, GMP facilities, and regulatory sandboxes, while industry contributes genomics-tuned HPC, hybrid architectures, and operational expertise. For example, the collaboration with CSIR-IGIB in Delhi enabled a 6.5x speed up in WGS and WES workflows through optimised hardware and software integration. Similar programs in Singapore are strengthening talent pipelines and accelerating the commercialisation of new MedTech solutions.

14. Looking ahead, what breakthroughs or platform-level innovations will be most transformative for APAC’s genomics landscape over the next five years?

AI will be the biggest catalyst for genomics in the APAC region. We will see AI-optimised CPU architectures that accelerate mapping and variant calling without relying on scarce GPUs, along with workflow engines that automate end-to-end analysis. Federated and hybrid AI models will enable population-scale insights while keeping sensitive data local. Combined with sustainable, high-density data centers and multi-omics integration, these advances will help the region scale precision health more efficiently and securely.